Icogen Corporation, a Seattle based biotechnology company, announced that the company is changing its name to Icogenex Corporation.
The name change reflects a refocusing and re-branding of the company. "We are now a different company from the one founded in 1995," stated Frederick Hagen, President & CEO. Historically, Icogen sought to utilize the strength of its core research team to clone, express, and market therapeutic proteins. Presently, Icogenex combines this longstanding expertise with new, proprietary screening methods, and focuses specifically on the development of anti-inflammatory therapeutics as well as the development of an Alzheimer's disease therapeutic.
"The name change marks the start of an exciting new, and directed focus for the company," added Dr Hagen. "We believe the strength of our internal research and development activities, paired with strategic partnering will allow us to develop and market therapeutic products at a significantly expedited pace."